001060 — JW Pharmaceutical Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapContrarian

Market Cap
KR₩511bn
Enterprise Value
KR₩572bn
Revenue
KR₩719bn

Annual balance sheet for JW Pharmaceutical, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	55,291	37,366	40,072	15,909	31,294
Net Total Accounts Receivable
Net Total Receivables	128,146	187,620	218,562	203,629	155,763
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	299,329	366,452	425,457	378,091	306,413
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	185,572	118,392	123,048	155,724	168,295
Net Goodwill
Net Intangible Assets
Long Term Investments
Long Term Notes Receivable
Other Long Term Assets
Total Assets	549,085	633,053	627,973	645,039	604,599
Accounts Payable
Payable / Accrued
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	234,748	282,678	380,131	286,927	208,615
Long Term Debt
Capital Lease Obligations
Total Long Term Debt
Total Debt
Deferred Income Tax
Minority Interest
Total Other Liabilities
Total Funded Status
Total Liabilities	341,594	431,858	387,619	379,598	275,112
Redeemable Preferred Stock
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Treasury Stock
Unrealized Gain / Loss
Other Equity
Total Equity	207,491	201,195	240,354	265,440	329,487
Total Liabilities & Shareholders' Equity	549,085	633,053	627,973	645,039	604,599
Total Common Shares Outstanding
Total Preferred Shares Outstanding